8 results about "High-mobility group" patented technology

The invention discloses a biomarker combination related to hypoxia-induced neuroinflammation and application of the biomarker combination, and belongs to the technical field of biomarker detection. The marker combination disclosed by the invention consists of serum S100 beta protein, neuron-specific enolase, interleukin-6, high-mobility group protein B1 and neurofilament light-chain protein. The marker combination can be used for stratification of nervous system injury risk of severe hypoxia patients and acquisition of prognosis evaluation data. According to the detection method disclosed by the invention, synchronous quantitative detection of five markers is realized by adopting a multiple immunofluorescent microsphere technology, and a marker combination scoring algorithm is established to comprehensively evaluate the severity of the hypoxia-related neuroinflammation.

The invention relates to an application of an indole base compound or a pharmaceutically acceptable salt of the indole base compound and a pharmaceutically acceptable carrier in preparation of a medicine or a skin care product for treating or preventing high HMGB1 (High Mobility Group Box 1) type skin diseases, the indole base compound comprises at least one functional group of quaternary ammonium cations, amino groups or amino groups containing substituent groups; the HMGB1 type skin disease is marked by an increase in the level of high mobility group protein B1 (HMGB1) or is abnormal in signal path. According to the present invention, the N37 residue of the HMGB1 can be specifically bound, the pathological release of the N37 residue from the cell nucleus to the cytoplasm can be accurately blocked, the physiological functions of the N37 residue in the nucleus and the like are not affected, and the potential side effect of the existing broad-spectrum HMGB1 inhibitor is overcome.

Provided are chimeric high mobility group (HMG) transcription factor polypeptides. In some aspects, provided are chimeric polypeptides comprising an N-terminal effector domain of a first HMG transcription factor and an HMG DNA binding domain and a C-terminal effector domain, wherein the HMG DNA binding domain or C-terminal effector domain is of a second HMG transcription factor. Also provided are cells (e.g., immune effector cells) that express a chimeric HMG transcription factor polypeptide of the present disclosure. In some instances, such cells (e.g., T cells) exhibit enhanced function relative to cells expressing only native wild-type HMG transcription factors. Also provided are methods of using such cells to treat a condition (e.g., cancer, infection, and / or the like) in a subject in need thereof.

The application belongs to the technical field of antitumor drugs, and particularly relates to a nanofiber hydrogel for synergistic antitumor sonodynamic / chemodynamic therapy, a preparation method and application thereof, synthesis of Nap-Pept, preparation of Nap-Pept / Fe 3+ / Cur nanogel, under ultrasonic conditions, synergistic sonodynamic therapy of a traditional Chinese medicine sonosensitizer Cur and Fe 3+ mediated chemodynamic therapy, triggering immunogenic death of cancer cells by increasing ROS levels of B16F10 cells and then damaging mitochondrial function. Nap-Pept / Fe 3+ / Cur@US promotes expression of the immune-related factor calnexin, release of high mobility group protein 1 and maturation of dendritic cells to kill tumor cells, thereby exerting an antitumor effect. In vivo and in vitro studies show that the anticancer effect of the combined sonodynamic and chemodynamic therapy is superior to that of single therapy, achieving the purpose of precise and efficient anti-melanoma.

The invention relates to a tissue marker for proton radiation heart injury and application of the tissue marker. The tissue marker comprises one or more of a transcription marker and a protein marker. Wherein the transcription marker comprises one or more of PIK3R5, CCR7, IL7R, CD7, CD22, CR2, CCL5 and VAV1, and the transcription marker comprises one or more of PIK3R5, CCR7, IL7R, CD7, CD22, CR2, CCL5 and VAV1; and the protein marker comprises one or more of SIRT1 and HMGB1 (High Mobility Group Box 1). According to the invention, the differential marker is used as a potential biomarker of the radioactive heart loss, and a research method for researching the radioactive heart loss by using a mouse model is provided, so that a demonstrative research is provided for multi-omics analysis of the radioactive heart loss and explanation of an action mechanism of the radioactive heart loss.

The invention belongs to the technical field of biosensing, and particularly relates to a biosensor for detecting high-mobility group protein B1 as well as a preparation method and application of the biosensor. The biosensor is an organic electrochemical transistor and comprises a substrate; the source electrode, the drain electrode and the gate electrode are arranged on the substrate; an organic semiconductor channel connecting the source electrode and the drain electrode; the nucleic acid aptamer molecular layer is fixed on the surface of the gate electrode and can be specifically combined with HMGB1; the sealing agent molecular layer is used for passivating uncombined sites on the surface of the gate electrode; and when the HMGB1 is combined with the aptamer, electrolyte ions are caused to be doped into an organic semiconductor channel, so that the output current is efficiently modulated, and rapid, high-sensitivity and high-specificity label-free electrical detection is realized. The biosensor is suitable for dynamic monitoring of HMGB1 in various diseases such as acute kidney injury and sepsis, and a novel tool is provided for disease early diagnosis and disease course management.

Provided herein is a synthetic polypeptide derived from High Mobility Group Box 1 (HMGB 1) host protein that can both disrupt bacterial biofilms and prevent Neutrophil Extracellular Trap (NET) formation. Also provided herein are methods to disrupt aberrant or excessive NET formation that are particularly well-suited to treat high-risk populations such as those infected with SARS CoV-2, sepsis, autoimmune diseases e.g., systemic lupus erythematosus, rheumatoid arthritis, Type I diabetes mellitus, small vessel vasculitis, autoinflammatory diseases e.g., gout, inflammatory bowel disease, and metabolic diseases e.g., Type 2 diabetes and obesity.

The present disclosure relates to a double-stranded ribonucleic acid for inhibiting HMGB1 gene expression, and modifiers, conjugates and uses thereof. Specifically, the present disclosure relates to a double-stranded ribonucleic acid, a double-stranded ribonucleic acid modifier, a double-stranded ribonucleic acid conjugate, a pharmaceutical composition and use for inhibiting expression of an HMGB1 gene, and a method for inhibiting expression of an intracellular HMGB1 gene. The double-stranded ribonucleic acid provided by the invention can be combined in cells to form an RNA induced silence complex (RISC), cut mRNA transcribed by the HMGB1 gene and efficiently and specifically inhibit the expression of the HMGB1 gene, is used for treating HMGB1 gene mediated diseases, and has an important application prospect in clinical disease treatment.